A Phase I Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of SPGL008 Monotherapy for Patients With Advanced Malignant Tumors
Latest Information Update: 08 Jul 2025
At a glance
- Drugs SPG L008 (Primary) ; SPG L008 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Shenyang Sunshine Pharmaceutical
Most Recent Events
- 08 Jul 2025 New trial record